$117.9 M

ANIX Mkt cap, 05-Feb-2021
Anixa Biosciences Net income (FY, 2020)-10.1 M
Anixa Biosciences EBIT (FY, 2020)-10 M
Anixa Biosciences Cash, 31-Oct-20206.4 M
Anixa Biosciences EV111.6 M

Anixa Biosciences Income Statement

Annual

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

450.4k449.2k248.1k249.5k2.1k1.2m9.1m25.0k95.0k100.0k362.5k750.0k362.5k

Cost of goods sold

3.6k737.0497.0714.027.1k

Gross profit

446.7k448.5k247.6k248.8k(24.9k)

Gross profit Margin, %

99%100%100%100%(1171%)

R&D expense

879.6k649.7k604.2k458.4k451.6k431.1k363.0k777.9k660.2k2.9m2.2m1.1m1.5m1.2m1.3m

General and administrative expense

774.7k686.0k521.6k433.7k2.0m1.9m2.2m1.9m1.8m1.1m1.8m2.0m1.4m1.3m1.1m923.3k859.9k699.3k1.5m990.0k908.8k2.7m2.1m1.1m1.1m1.4m1.2m

Operating expense total

1.7m1.3m1.1m892.1k2.0m1.9m2.2m1.9m1.8m1.1m1.8m2.0m1.4m1.3m1.1m923.3k1.3m1.1m1.9m1.8m1.6m5.6m4.3m2.1m2.6m2.7m2.4m

Depreciation and amortization

81.4k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k81.3k251.3k41.9k

EBIT

(1.2m)(887.3k)(878.2k)(643.3k)(2.1m)(1.9m)(2.2m)(2.0m)(1.4m)(159.6k)3.9m(2.1m)(1.5m)(1.5m)(1.1m)(974.9k)(1.4m)(1.2m)(1.7m)(1.9m)(1.4m)(5.6m)(5.0m)(2.2m)(2.6m)(2.7m)(2.4m)

EBIT margin, %

(268%)(198%)(354%)(258%)(97315%)(13%)42%(8533%)(1569%)(975%)(477%)(187%)(1546%)

Interest expense

22.2k835.5k125.0k7.3k

Interest income

653.01.2k1.1k773.07.030.076.01.4k1.9k1.5k4.7k5.2k4.5k3.3k3.5k3.5k999.0626.08.2k9.1k8.4k12.2k17.1k18.4k13.3k12.1k

Pre tax profit

(1.2m)(886.1k)(877.1k)(629.1k)(2.1m)(2.5m)(2.6m)(3.6m)(3.2m)411.0k3.8m(2.2m)(1.6m)(1.6m)(1.3m)(1.1m)(1.6m)160.5k(1.8m)(1.9m)(1.4m)(5.6m)(5.0m)(2.2m)(2.6m)(2.7m)

Income tax expense

600.0k

Net Income

(1.8m)(886.1k)(877.1k)(629.1k)(2.1m)(2.5m)(2.6m)(3.6m)(3.2m)411.0k3.8m(2.2m)(1.6m)(1.6m)(1.3m)(1.1m)(3.6m)160.5k(1.8m)(1.8m)(1.4m)(5.5m)(5.0m)(2.2m)(2.6m)(2.7m)(2.6m)

Anixa Biosciences Balance Sheet

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

551.4k463.0k130.7k101.5k1.7m1.3m982.0k776.1k617.7k3.7m7.8m6.1m5.2m4.0m2.6m2.0m1.4m2.9m1.8m2.8m4.2m2.6m4.2m3.8m4.4m2.8m2.9m5.9m

Accounts Receivable

828.4k133.3k45.0k221.0k797.0k1.1k22.3k32.3k6.0k

Prepaid Expenses

61.0k97.2k107.5k93.3k67.0k52.1k47.3k141.3k134.2k100.6k66.5k42.5k193.6k55.8k39.0k56.4k68.6k64.6k140.3k278.5k298.2k378.5k333.7k124.3k129.6k154.5k116.3k189.8k

Inventories

33.4k

Current Assets

3.6m2.6m1.8m1.1m1.8m1.3m1.0m3.4m3.6m6.4m10.6m8.5m7.8m6.2m4.8m4.0m2.1m5.2m6.4m5.8m5.7m5.7m6.2m7.5m6.6m5.9m5.7m9.3m

PP&E

17.9k14.7k13.6k11.9k11.3k7.7k9.1k7.7k8.3k9.9k59.0k51.1k47.3k145.6k170.7k163.2k160.3k149.5k141.4k50.8k57.1k72.1k66.5k230.0k215.1k201.4k186.9k

Total Assets

10.2m8.0m6.8m5.9m7.5m7.4m5.3m10.3m10.5m13.4m13.3m11.1m10.3m8.6m7.2m6.3m4.2m7.2m8.4m7.5m7.4m7.3m6.5m7.8m6.8m6.2m5.9m9.4m

Accounts Payable

278.4k449.1k558.7k462.9k489.2k534.0k516.0k491.8k457.8k529.3k577.6k388.8k424.7k560.4k418.1k444.8k540.7k448.4k444.7k416.9k452.1k419.4k612.9k717.9k567.8k367.1k170.8k339.3k

Short-term debt

1.8m970.0k325.0k738.4k151.8k233.1k395.8k477.1k558.4k721.1k802.4k883.7k1.0m1.1m1.2m1.4m1.5m1.5m53.4k55.7k58.2k

Current Liabilities

2.9m2.1m2.1m1.8m3.4m3.3m3.1m11.5m10.7m8.4m1.7m688.7k711.7k1.2m706.9k531.6k3.7m3.7m2.9m1.1m1.3m1.1m1.3m1.6m1.4m1.1m1.1m1.2m

Long-term debt

407.7k1.8m259.8k1.5m1.6m1.8m40.8k26.0k10.6k

Total Debt

2.2m2.7m584.8k2.3m1.8m2.0m395.8k477.1k558.4k721.1k802.4k883.7k1.0m1.1m1.2m1.4m1.5m1.5m94.2k81.7k68.8k

Total Liabilities

13.2m5.0m4.1m4.3m5.1m4.6m4.6m8.0m3.7m2.9m1.2m1.1m1.2m

Common Stock

1.7m1.8m1.8m1.8m1.9m2.0m2.1m2.1m2.2m2.4m2.2m2.2m87.2k87.3k87.4k87.5k87.6k116.9k151.2k166.3k168.5k187.0k194.7k200.1k201.6k208.4k214.8k236.5k

Preferred Stock

350.0k350.0k14.0k14.0k14.0k14.0k

Additional Paid-in Capital

124.3m125.8m126.0m126.3m128.7m130.6m133.1m136.2m140.2m144.4m146.7m147.7m150.8m151.2m151.5m151.7m148.8m156.1m159.7m164.3m165.3m171.0m180.3m183.9m185.3m189.6m192.1m198.0m

Retained Earnings

(118.0m)(121.7m)(122.6m)(123.2m)(127.2m)(129.7m)(132.2m)(138.8m)(142.0m)(141.6m)(141.0m)(143.3m)(144.9m)(147.7m)(149.0m)(150.1m)(152.8m)(152.6m)(154.4m)(158.0m)(159.4m)(164.9m)(175.1m)(177.6m)(179.7m)(184.4m)(187.0m)(189.6m)

Total Equity

2.2m738.0k(339.0k)(893.1k)(1.3m)(1.4m)(3.2m)(5.7m)(4.8m)149.7k8.3m7.0m6.0m3.6m2.6m1.7m(3.8m)3.6m5.5m6.4m6.0m6.2m5.1m6.2m5.4m5.0m4.8m8.1m

Financial Leverage

4.5 x10.9 x-20 x-6.6 x-5.7 x-5.1 x-1.6 x-1.8 x-2.2 x89.5 x1.6 x1.6 x1.7 x2.4 x2.8 x3.7 x-1.1 x2 x1.5 x1.2 x1.2 x1.2 x1.3 x1.3 x1.3 x1.2 x1.2 x1.2 x

Anixa Biosciences Cash Flow

Quarterly

USDQ3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(4.6m)(886.1k)(1.8m)(2.4m)(2.1m)(4.6m)(7.2m)(3.6m)(6.9m)(6.5m)3.8m1.5m(86.6k)(1.6m)(2.9m)(4.0m)(1.6m)(1.4m)(3.2m)(1.9m)(3.3m)(8.9m)(5.0m)(7.5m)(9.7m)(2.6m)(5.3m)(7.9m)

Depreciation and Amortization

6.0k2.1k3.9k5.6k1.4k70.5k151.8k233.1k81.3k162.6k244.0k85.2k162.6k244.0k91.8k183.9k276.1k85.7k170.0k256.4k257.4k395.0k451.7k15.0k29.4k38.3k

Accounts Receivable

175.0k(653.4k)41.7k355.0k400.0k400.0k(221.0k)(490.0k)305.9k44.2k34.2k(60.6k)

Inventories

20.8k(2.1k)

Accounts Payable

(96.7k)150.2k238.3k132.3k436.1k508.9k572.2k(60.0k)(14.7k)28.1k152.2k(804.0k)(813.3k)655.5k132.0k150.9k201.2k161.3k437.3k(63.4k)(28.2k)(60.9k)30.9k135.9k(14.2k)(218.7k)(415.0k)(246.5k)

Cash From Operating Activities

(3.5k)(657.3k)(1.5m)(2.2m)(890.0k)(1.8m)(2.6m)(1.2m)(1.7m)(2.0m)4.7m2.9m2.2m(532.4k)(1.9m)(2.7m)(729.9k)(1.8m)(3.1m)(1.3m)(2.1m)(3.3m)(1.3m)(2.8m)(3.4m)(1.9m)(3.5m)(4.8m)

Purchases of PP&E

(9.0k)(850.0)(1.6k)(1.6k)(2.5k)(714.0)(1.8k)(54.8k)(54.8k)(54.8k)(106.0k)(141.1k)(144.6k)(14.1k)(14.1k)(16.9k)(2.5k)(11.8k)(31.9k)(175.5k)(175.5k)(15.8k)(15.8k)(15.8k)

Cash From Investing Activities

(2.9m)199.0k698.1k1.3m498.7k500.4k499.3k(2.4m)(2.1m)(2.6m)(204.8k)45.2k45.2k144.0k108.9k355.4k135.9k(1.5m)(3.5m)847.5k2.2m718.1k250.0k(925.5k)(275.5k)(535.8k)(285.8k)(805.8k)

Long-term Borrowings

(200.0k)

Cash From Financing Activities

2.3m147.3k208.5k208.5k1.8m2.2m2.8m3.5m3.5m7.3m(200.0k)(410.9k)18.2k23.4k(494.3k)3.7m5.9m677.4k1.8m2.2m4.5m5.0m1.8m3.2m8.0m

Net Change in Cash

(542.7k)(311.0k)(643.3k)(672.5k)1.4m934.1k642.3k(122.0k)(280.5k)2.8m4.4m2.7m1.8m(388.4k)(1.8m)(2.3m)(1.1m)388.6k(654.6k)(492.5k)833.1k(748.3k)1.1m766.4k1.3m(669.7k)(603.4k)2.4m

Anixa Biosciences Ratios

USDQ3, 2011

Financial Leverage

4.5 x